Encore Global Management LP Takes $850,000 Position in Regeneron Pharmaceuticals, Inc. $REGN

Encore Global Management LP bought a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in the 1st quarter, HoldingsChannel.com reports. The firm bought 1,100 shares of the biopharmaceutical company’s stock, valued at approximately $850,000.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. WPG Advisers LLC boosted its holdings in Regeneron Pharmaceuticals by 312.5% in the fourth quarter. WPG Advisers LLC now owns 33 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 25 shares in the last quarter. SHP Wealth Management acquired a new stake in Regeneron Pharmaceuticals in the fourth quarter valued at approximately $26,000. Titan Wealth CI Ltd bought a new stake in shares of Regeneron Pharmaceuticals during the fourth quarter valued at approximately $29,000. Kemnay Advisory Services Inc. bought a new stake in shares of Regeneron Pharmaceuticals during the fourth quarter valued at approximately $31,000. Finally, Birchwood Financial Partners Inc. acquired a new position in shares of Regeneron Pharmaceuticals during the fourth quarter worth approximately $32,000. 83.31% of the stock is owned by institutional investors.

Regeneron Pharmaceuticals News Summary

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Analysts expect Regeneron’s second-quarter performance to be supported by continued demand for Dupixent, Eylea HD and Libtayo. Investors will also watch for updates on share repurchases, earnings guidance and the broader development pipeline. Will REGN’s Q2 Earnings Get a Boost From Dupixent and Eylea HD?
• Neutral Sentiment: Multiple law firms announced or promoted securities class actions against Regeneron and certain executives. The cases generally cover investors who purchased shares from August 1, 2025, through May 15, 2026, with September 14, 2026, cited as the lead-plaintiff deadline. The notices primarily repeat earlier allegations and are not new operating developments. Faruqi & Faruqi Equity Action Notice
• Negative Sentiment: The legal actions stem from disclosures about Regeneron’s Phase 3 Fianlimab-Libtayo melanoma trial. Reports allege that investors were not fully informed as the trial moved from delayed event accruals to a protocol amendment and ultimately failed to meet its primary endpoint. The trial failure reportedly contributed to an approximately 9%–10% share-price decline and erased about $11 billion in market value, raising concerns about pipeline execution and potential litigation costs. Hagens Berman Regeneron Trial Alert

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on REGN shares. Royal Bank Of Canada cut their target price on Regeneron Pharmaceuticals from $707.00 to $696.00 and set a “sector perform” rating on the stock in a report on Tuesday, July 7th. Canaccord Genuity Group decreased their price target on shares of Regeneron Pharmaceuticals from $1,057.00 to $875.00 and set a “buy” rating for the company in a research note on Tuesday, May 19th. Morgan Stanley lowered their price objective on shares of Regeneron Pharmaceuticals from $788.00 to $730.00 and set an “equal weight” rating on the stock in a report on Wednesday, July 8th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a research note on Wednesday, June 24th. Finally, Wall Street Zen cut shares of Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, July 4th. One analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and nine have issued a Hold rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $787.88.

Regeneron Pharmaceuticals Stock Up 4.2%

REGN stock opened at $695.18 on Wednesday. Regeneron Pharmaceuticals, Inc. has a twelve month low of $541.00 and a twelve month high of $821.11. The company has a quick ratio of 2.96, a current ratio of 3.57 and a debt-to-equity ratio of 0.06. The stock’s 50 day moving average is $637.83 and its 200-day moving average is $712.50. The firm has a market capitalization of $73.49 billion, a PE ratio of 16.94, a P/E/G ratio of 1.48 and a beta of 0.24.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Wednesday, April 29th. The biopharmaceutical company reported $9.47 earnings per share (EPS) for the quarter, beating the consensus estimate of $8.91 by $0.56. Regeneron Pharmaceuticals had a return on equity of 13.16% and a net margin of 29.65%.The company had revenue of $3.61 billion for the quarter, compared to analysts’ expectations of $3.48 billion. During the same quarter in the previous year, the firm earned $8.22 earnings per share. Regeneron Pharmaceuticals’s quarterly revenue was up 19.0% on a year-over-year basis. Sell-side analysts expect that Regeneron Pharmaceuticals, Inc. will post 37.12 EPS for the current fiscal year.

Insider Buying and Selling

In other Regeneron Pharmaceuticals news, Director Arthur F. Ryan sold 200 shares of the firm’s stock in a transaction on Thursday, July 2nd. The stock was sold at an average price of $650.15, for a total transaction of $130,030.00. Following the transaction, the director directly owned 17,303 shares in the company, valued at approximately $11,249,545.45. This trade represents a 1.14% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 6.97% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.